PRESS RELEASE 2023

Ferring Pharmaceuticals’ Fertility Out Loud Docuseries follows four U.S.-based couples as they face their unique fertility journeys head-on Episode one of the four-part series is now available on the Fertility Out Loud YouTube channel Parsippany, NJ – November 29, 2023 – Ferring Pharmaceuticals t...

36-month follow-up data from the Phase 3 study demonstrate one-quarter of patients with high-risk, BCG-unresponsive NMIBC remained free of high-grade recurrence  Trial showed a 90% three-year overall survival rate, with more than half of cystectomy-free patients at 36 months Follow-up analysis of...

Parsippany, NJ – November 15, 2023 – Ferring Pharmaceuticals appreciates the ongoing support from New Jersey and Minnesota as both states recognize November as Clostridioides difficile (C. diff) Infection Awareness Month. This is the fourth year in a row that the offices of Governor Phil Murphy (...

New analysis evaluates the association between gut microbiome composition and health-related quality of life for patients with recurrent C. diff infection A new ad hoc subgroup analysis evaluates efficacy and safety of REBYOTA in patients 65 years of age or older with underlying illnesses Parsipp...

“Transformational” Gift will Establish the “Ferring Endowment for the Education of Healthcare Professionals in Training” Washington, DC and Parsippany, NJ – The American Society for Reproductive Medicine (ASRM) and Ferring Pharmaceuticals today announced a historic $5 million endowment from Ferri...

Analysis looks at early experience with REBYOTA in clinical practice Additional analyses evaluate efficacy and safety of REBYOTA in patients with kidney disease and whether patients treated with REBYOTA remained recurrence free after antibiotic therapy for another illness Analysis from pivotal Ph...

Parsippany, NJ – October 3, 2023 – Ferring Pharmaceuticals today announced it will present two analyses of data for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose, FDA approved microbiome-based treatment to prevent recurrent Clostridioides difficile (C. diff) infection a...

Fortune’s “Change the World” List recognises companies that have had a positive social impact through activities that are part of their core business strategy. Fortune highlights Ferring’s #ProjectFamily Safe Birth Commitment, which aims to reduce maternal mortality in low and lower-middle income...

Parsippany, NJ – September 21, 2023 – Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose, FDA approved microbiome-based treatment to prevent recurrent Clostridioides difficile (C. diff) infection af...

Urologists treating eligible high-risk bladder cancer patients at participating early experience program clinics in the U.S. can now prescribe the first and only FDA-approved intravesical gene therapy Ferring launches ABLE-41 Real World Evidence Study, a patient registry to explore early use, exp...

Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) Transaction provides Ferring with significant non-dilutive capital to suppor...

Integrated analysis is the largest safety evaluation to date of any microbiota-based live biotherapeutic and includes safety data for up to two years REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, fol...

Parsippany, NJ – June 26, 2023 – Ferring Pharmaceuticals today announced it will make the intravesical gene-therapy ADSTILADRIN® (nadofaragene firadenovec-vncg) available for physicians to prescribe to their patients through an Early Experience Program beginning September 2023 in recognition of t...

Approval of Prior-Approval Supplement will help to ensure the future, long-term supply and clinical activities for Ferring’s novel intravesical gene therapy for non-muscle invasive bladder cancer (NMIBC) Two new manufacturing sites, including one of the world’s largest viral vector facilities, cu...

The primary endpoint was met: SI-6603 showed statistically significant improvement in worst leg pain score versus control at 13 weeks after injection. SI-6603 was generally well-tolerated. Ferring’s clinical development partner, Seikagaku Corporation, plans to proceed with preparation for a Biolo...

Data presentations highlight Ferring’s microbiome leadership and commitment to ongoing research Analyses review safety and efficacy data across various patient populations with co-morbidities and when treatment is administered by colonoscopy Additional analysis evaluates shifts in microbiom...

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection Analysis is the first to evaluate safety and efficacy of REBYOTA in a real-world populatio...

National Infertility Awareness Week® seeks to inspire, educate and activate the fertility community to speak up about infertility to help drive change.  Parsippany, NJ, USA – April 24, 2023 – Ferring Pharmaceuticals today announced its unwavering support of National Infertility Awareness Week® (N...

Parsippany, NJ, USA – April 18, 2023 – Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA™ (fecal microbiota, live – jslm) at Digestive Disease Week® (DDW 2023). The congress will take place May 6-9, 2023, in Chicago, Ill. REBYOTA is the first microbiome-based tr...

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection REBYOTA is now available by prescription in the United States Ferring is committed to maki...